A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2017
At a glance
- Drugs Bexagliflozin (Primary) ; Exenatide
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Theracos
- 21 Jun 2017 Planned End Date changed from 2 Jun 2017 to 29 Jun 2017.
- 21 Jun 2017 Planned primary completion date changed from 2 Jun 2017 to 29 Jun 2017.
- 21 Jun 2017 Status changed from not yet recruiting to active, no longer recruiting.